Newly Arrival Irinotecan Hydrochloride Trihydrate - (R)-Lansoprazole Dexlansoprazole CAS 138530-94-6 Assay 98.0~102.0% (HPLC) Factory – Ruifu

Ruifu Chemical Supply Lansoprazole Intermediates
Lansoprazole CAS 103577-45-3
Lansoprazole Chloride Compound CAS 127337-60-4
(R)-Lansoprazole Dexlansoprazole CAS 138530-94-6

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer’s requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

(R)-Lansoprazole (CAS: 138530-94-6) is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Dexlansoprazole for Lansoprazole dextroisomer, is a kind of anti peptic ulcer drugs for substituted benzimidazole derivatives, in the molecular structure into the element fluorine, second proton pump inhibitors omeprazole after. Dexlansoprazole has the effect of inhibiting the secretion of gastric acid, the effect is better than that of other drugs (Omeprazole, Pantoprazole, Rebela, Tetrazolium) can significantly inhibit the occurrence of ulcer. It is superior to famotidine or Omeprazole for the damage of alcohol induced gastric mucosa and duodenal ulcer mainly caused by acid hypersecretion. In addition, the product has the same anti Helicobacter pylori effect as the bismuth preparation, and is used for reflux esophagitis and Zhuo AI syndrome. Takeda Pharmaceuticals received approval of dexlansoprazole, a dual release formulation of the (R)-isomer of lansoprazol proton pump inhibitor (PPI) already in the market, from the FDA in January 2009. Dexlansoprazole is a delayed release capsule for the oncedaily, oral treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.